abstract |
The present invention relates to a pharmaceutical combination comprising an AT 1-receptor blocker or a pharmaceutically acceptable salt thereof and an mTOR inhibitor, such as rapamycin or rapamycin derivative, optionally in the presence of a pharmaceutically acceptable carrier. . |